†A Pilot Study of Triglyceride Screening in Blood Donors

Stephen Eason,Frances Compton,Merlyn Sayers,Amit Khera,Zahid Ahmad,Caroline Abe

DOI: https://doi.org/10.1016/j.jacl.2024.04.056

IF: 5.365

2024-07-26

Journal of Clinical Lipidology

Abstract:Study Funding Ionis Young Investigators Award. Background/Synopsis Few attempts at community-based screening have been made for triglyceride levels, which has the potential to identify individuals at risk for cardiovascular disease as well as acute hypertriglyceridemic pancreatitis. One opportunity for such screening is among blood donors. Objective/Purpose Demonstrate feasibility of measuring non-fasting triglyceride level in blood donors. Methods We prospectively measured non-fasting triglyceride levels (Beckman Coulter assay, California) among volunteer blood donors at Carter BloodCare North Texas over 3 weeks from December 2023 to January 2024. Donor self-reported demographic data included age, gender, ethnicity/race and BMI. Blood pressure and total cholesterol level were checked per routine protocol at Carter BloodCare. Per the 2021 ACC expert consensus on management of hypertriglyceridemia, non-fasting triglyceride levels were stratified into normal 500 mg/dL hypertriglyceridemia. Results reported as median (IQR). Results 10,175 unique blood donors had a triglyceride level measured [35.2% female, age 53 years (42-62), BMI 29.4 (26-33), 71.6% White]. Additionally, 98 individuals donated multiple times [first triglyceride 141 mg/dL (99-198), second triglyceride 142 mg/dL (103-205), interpersonal absolute change in triglyceride +/- 39.5 mg/dL (17-86)]. Among unique donors, triglyceride levels ranged from 23-2342 mg/dL (median 154 mg/dL, mean 185 mg/dL). Of note, 7 donors had triglycerides >1000 mg/dL (min 1051- max 2342). Overall, 58.4% had normal triglycerides [triglyceride 111 mg/dL (84-140), 41.6% female, age 52 years (40-62), BMI 28.4 (25-32), 71.7% White; 16.9% elevated blood pressure, total cholesterol 169 mg/dL (146-193)]; 39.2% had moderate hypertriglyceridemia [triglyceride 243 mg/dL (204-309), 26.8% female, age 53 years (43-61), BMI 30.5 (27.4-34.2), 71.8% White, 21.9% elevated blood pressure, total cholesterol 181 mg/dL (156-206)]; 2.4% severe hypertriglyceridemia [triglyceride 582 (539-705), 17% female, age 52 years (44-59), BMI 30.9 (28-35), 67.5% White, 27.6% elevated blood pressure, total cholesterol 209 mg/dL (178-235)]. Triglyceride levels were associated with male gender (p < 0.001), high blood pressure (p < 0.001), high cholesterol (p < 0.001), and Hispanic ethnicity (p<0.001). Conclusions Our pilot study demonstrates the feasibility of non-fasting community-based screening for hypertriglyceridemia among volunteer blood donors. Such efforts can rapidly screen triglycerides in many individuals. Furthermore, such screening has the potential to identify individuals at risk for cardiovascular disease (moderate hypertriglyceridemia) and acute pancreatitis (severe hypertriglyceridemia). Future efforts will explore donors' understanding of triglycerides, identification of their risk factors for hypertriglyceridemia, along with the need for education and a pathway for their care.

pharmacology & pharmacy